Literature DB >> 25629991

SOX11, CCND1, BCL1/IgH and IgH-VDJ: a battle of minimal residual disease markers in mantle cell lymphoma?

Anita T Simonsen1, Marie Schou1, Camilla D Sørensen1, Hans H N Bentzen1, Charlotte G Nyvold1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25629991     DOI: 10.3109/10428194.2015.1004672

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  5 in total

1.  SOX11 regulates the pro-apoptosis signal pathway and predicts a favorable prognosis of mantle cell lymphoma.

Authors:  Wenjuan Yang; Yanying Wang; Zhen Yu; Zengjun Li; Gang An; Wei Liu; Rui Lv; Liping Ma; Shuhua Yi; Lugui Qiu
Journal:  Int J Hematol       Date:  2017-04-20       Impact factor: 2.490

2.  SOX11 expression as a MRD molecular marker for MCL in comparison with t(11;14) and IGH rearrangement.

Authors:  Małgorzata Szostakowska; Michał Szymczyk; Kalina Badowska; Barbara Tudek; Anna Fabisiewicz
Journal:  Med Oncol       Date:  2018-03-08       Impact factor: 3.064

Review 3.  Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside.

Authors:  Xinyue Deng; Meilan Zhang; Jianfeng Zhou; Min Xiao
Journal:  Exp Hematol Oncol       Date:  2022-09-03

Review 4.  Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.

Authors:  Arati A Inamdar; Andre Goy; Nehad M Ayoub; Christen Attia; Lucia Oton; Varun Taruvai; Mark Costales; Yu-Ting Lin; Andrew Pecora; K Stephen Suh
Journal:  Oncotarget       Date:  2016-07-26

Review 5.  Advances in the assessment of minimal residual disease in mantle cell lymphoma.

Authors:  Dayoung Jung; Preetesh Jain; Yixin Yao; Michael Wang
Journal:  J Hematol Oncol       Date:  2020-09-24       Impact factor: 17.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.